Company Description
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.
Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
The company’s wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste.
Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions.
The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States.
MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 837 |
| CEO | Joseph Capper |
Contact Details
Address: 1775 West Oak Commons Court, NE Marietta, Georgia 30062 United States | |
| Phone | 770 651 9100 |
| Website | mimedx.com |
Stock Details
| Ticker Symbol | MDXG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001376339 |
| CUSIP Number | 602496101 |
| ISIN Number | US6024961012 |
| Employer ID | 26-2792552 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Joseph H. Capper | Chief Executive Officer and Director |
| Douglas C. Rice CPA | Chief Financial Officer |
| William F. Hulse IV | General Counsel and Chief Administrative Officer |
| Scott M. Turner | Senior Vice President of Operations and Procurement |
| Matthew M. Notarianni | Head of Investor Relations |
| Mark P. Graves | Senior Vice President and Chief Compliance Officer |
| Hilary Dixon | Vice President of Investor Relations and Corporate Strategic Communications |
| Kate Surdez | Chief Human Resources Officer |
| Dr. David H. Mason Jr. | Chief Medical Officer |
| Dr. Robert Benjamin Stein M.D., Ph.D. | President of Regenerative Medicine and Biologics Innovation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2025 | 144 | Filing |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 10-K | Annual Report |
| Jan 14, 2025 | 8-K | Current Report |
| Dec 16, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |